Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Precigen, Inc. (PGEN : NSDQ)

• Company Description    Precigen Inc. is a biopharmaceutical company. It specialise in the development of gene and cell therapies for immuno-oncology, autoimmune disorders and infectious diseases. The company's transformative therapeutic platforms, including UltraCAR-T(TM), AdenoVerse(TM) cytokine therapies, multifunctional therapeutics and off-the-shelf AdenoVerse(TM) immunotherapies, as well as ActoBio Therapeutics, Exemplar Genetics and Triple-Gene from our subsidiaries. Precigen Inc., formerly known as Intrexon Corporation, is based in Germantown, Maryland. Number of Employees: 160

• Price / Volume Information    Yesterday's Closing Price: $4.24 Daily Weekly Monthly 20 Day Moving Average: 3,355,429 shares Shares Outstanding: 356.51 (millions) Market Capitalization: $1,511.61 (millions) Beta: 1.07 52 Week High: $5.47 52 Week Low: $1.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.07% 1.84% 12 Week 11.29% 2.88% Year To Date 1.44% -5.86%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 20374 Seneca Meadows Parkway - Germantown,MD 20876 USA ph: 301-556-9900 fax: - investors@precigen.com http://www.precigen.com

• General Corporate Information    Officers Helen Sabzevari - Chief Executive Officer Randal J. Kirk - Executive Chairman Harry Thomasian Jr. - Chief Financial Officer Nancy H. Agee - Director Cesar L. Alvarez - Director Peer Information Precigen, Inc. (CORR.) Precigen, Inc. (RSPI) Precigen, Inc. (CGXP) Precigen, Inc. (BGEN) Precigen, Inc. (GTBP) Precigen, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 74017N105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 356.51 Most Recent Split Date: (:1) Beta: 1.07 Market Capitalization: $1,511.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $0.00 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $0.04 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: 106.00 Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 74.70 Price/Cash Flow: - Price / Sales: 47.84 EPS Growth vs. Year Ago Period: 71.43% vs. Previous Quarter: -100.00% Sales Growth vs. Year Ago Period: 1,633.93% vs. Previous Quarter: 409.35% ROE 03/31/26 - 717.50 12/31/25 - 2,317.96 09/30/25 - 1,066.10 ROA 03/31/26 - 58.48 12/31/25 - 49.65 09/30/25 - 57.56 Current Ratio 03/31/26 - 4.82 12/31/25 - 3.09 09/30/25 - 4.04 Quick Ratio 03/31/26 - 4.12 12/31/25 - 2.83 09/30/25 - 3.95 Operating Margin 03/31/26 - 262.49 12/31/25 - 714.49 09/30/25 - 1,248.01 Net Margin 03/31/26 - -646.99 12/31/25 - -2,588.21 09/30/25 - -3,912.92 Pre-Tax Margin 03/31/26 - -646.98 12/31/25 - -2,588.18 09/30/25 - -3,914.25 Book Value 03/31/26 - 0.06 12/31/25 - 0.06 09/30/25 - 0.14 Inventory Turnover 03/31/26 - 0.92 12/31/25 - 1.53 09/30/25 - 5.75 Debt-to-Equity 03/31/26 - 4.62 12/31/25 - 4.46 09/30/25 - 2.22 Debt-to-Capital 03/31/26 - 82.21 12/31/25 - 81.67 09/30/25 - 68.93

Powered by Zacks Investment Research ©